Target Name: MEGF8
NCBI ID: G1954
Other Name(s): Multiple epidermal growth factor-like domains protein 8 (isoform 2) | multiple EGF like domains 8 | MGC120684 | CRPT2 | C19orf49 | MGC138147 | Multiple EGF-like domain protein 4 | HBV pre-s2 binding protein 1 | EGFL4 | EGF-like-domain, multiple 4 | Multiple epidermal growth factor-like domains protein 8 | FLJ22365 | epidermal growth factor-like protein 4 | hepatitis B virus pre-S2-binding protein 1 | SBP1 | EGF-like domain-containing protein 4 | Multiple EGF-like domains protein 8 | MEGF8 variant 2 | HBV pre-S2-binding protein 1 | Epidermal growth factor-like protein 4 | Multiple epidermal growth factor-like domains 8 | EGF-like protein 4 | MEGF8_HUMAN | Multiple EGF like domains 8, transcript variant 2

MEGF8: A Drug Target / Disease Biomarker

MEGF8, also known as miR-202, is a non-coding RNA molecule that has been shown to play a critical role in the development and progression of various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed new light on its potential as a drug.

Mutations in the MEGF8 gene have been linked to a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its expression has also been shown to be regulated by a variety of factors, including DNA damage, cellular stress, and environmental factors.

One of the most promising aspects of MEGF8 is its potential as a drug target. The use of small molecules, such as drugs that bind to specific RNA structures, has been shown to be an effective way to target and regulate gene expression in a variety of organisms. By inhibiting the activity of MEGF8, researchers may be able to reduce the risk of disease associated with its high expression levels.

In addition to its potential as a drug target, MEGF8 has also been shown to be a valuable biomarker for a number of diseases. Its expression has been associated with a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. By detecting the expression of MEGF8 in biological samples, researchers may be able to diagnose and monitor the progression of these diseases.

One of the most promising applications of MEGF8 as a biomarker is its potential to detect cancer at an early stage. Its expression has been shown to be highly elevated in the tissues of cancer patients, making it an attractive target for cancer diagnostics. In addition, its expression has also been associated with the development of various types of cancer, including breast, ovarian, and prostate cancers.

In addition to its potential as a drug and biomarker, MEGF8 has also been shown to play a critical role in the regulation of cellular processes. Its expression has been shown to be regulated by a variety of factors, including DNA damage, cellular stress, and environmental factors. These regulation mechanisms may have implications for the development of new treatments for a variety of diseases.

In conclusion, MEGF8 is a non-coding RNA molecule that has been shown to play a critical role in the development and progression of various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed new light on its potential as a drug and biomarker. Further research is needed to fully understand its mechanisms of action and its potential as a therapeutic agent.

Protein Name: Multiple EGF Like Domains 8

Functions: Acts as a negative regulator of hedgehog signaling

More Common Targets

MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor | Melanoma-Associated Antigen | Melatonin receptor | MELK | MELTF | MELTF-AS1 | Membrane-Bound Protein Tyrosine Phosphatases (rPTPs) | Membrane-spanning 4-domains subfamily A member 4A | MEMO1 | MEMO1P1 | MEMO1P4 | MEMO1P5 | MEN1 | MEOX1 | MEOX2 | MEP1A | MEP1AP2 | MEP1AP4 | MEP1B | MEPCE | MEPE | MERTK | MESD | MESP1 | MESP2 | MEST | MESTIT1 | MESTP3 | MESTP4 | MET | Metabotropic glutamate (mGluR) receptor | Metallothionein | METAP1 | METAP1D | METAP2 | Metaxin complex | Methionine adenosyltransferase | Methionine adenosyltransferase II | Methionyl aminopeptidase | Methylcytosine dioxygenase (TET) | METRN | METRNL | METTL1 | METTL13 | METTL14 | METTL15 | METTL15P1 | METTL15P2 | METTL16 | METTL17 | METTL18 | METTL21A | METTL21C | METTL21EP | METTL22 | METTL23 | METTL24 | METTL25 | METTL25B | METTL26 | METTL27 | METTL2A | METTL2B | METTL3 | METTL4 | METTL5 | METTL6 | METTL7A | METTL7B | METTL8 | METTL9 | MEX3A | MEX3B | MEX3C | MEX3D | MFAP1 | MFAP2 | MFAP3 | MFAP3L | MFAP4 | MFAP5 | MFF | MFF-DT